American Oriental Bioengineering Inc. (OTCMKTS:AOBI) was downgraded by equities researchers at ValuEngine from a “hold” rating to a “sell” rating in a report released on Monday, July 17th.
Shares of American Oriental Bioengineering (OTCMKTS AOBI) opened at 1.11 on Monday. American Oriental Bioengineering has a 52-week low of $1.02 and a 52-week high of $5.40. The stock has a 50 day moving average of $3.08 and a 200 day moving average of $3.94. The company’s market cap is $79920.00.
About American Oriental Bioengineering
American Oriental Bioengineering, Inc is an integrated pharmaceutical company. The Company is engaged in development, manufacture and commercialization of a broad range of pharmaceutical and healthcare products. The Company’s business consists of prescription pharmaceutical products, over-the-counter pharmaceutical products and nutraceutical products.
To view ValuEngine’s full report, visit ValuEngine’s official website.
What are top analysts saying about American Oriental Bioengineering Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for American Oriental Bioengineering Inc. and related companies.